Top

Published in:

01-04-2021 | Lymphoma | News item

TNF-alpha inhibitors: potential risk of mycosis fungoides

Published in: Reactions Weekly | Issue 1/2021

Excerpt

Tumour necrosis factor (TNF)-alpha inhibitors including infliximab (Remicade), adalimumab (Humira), etanercept (Enbrel) and etanercept biosimilar (Erelzi) may be associated with a potential risk of mycosis fungoides, a form of cutaneous T-cell lymphoma, reports Health Canada in a Summary Safety Review. …

Health Canada. Summary Safety Review - Remicade (infliximab), Humira (adalimumab), Enbrel (etanercept) and Erelzi (biosimilar etanercept) - Health Canada. Internet Document : 18 Mar 2021. Available from: URL: https://hpr-rps.hres.ca/reg-content/summary-safety-review-detail.php?lang=en&linkID=SSR00260

Title: TNF-alpha inhibitors: potential risk of mycosis fungoides
Publication date: 01-04-2021
Publisher: Springer International Publishing
Keywords: Lymphoma
Etanercept
Adalimumab
Mycosis Fungoides
Infliximab
Published in: Reactions Weekly / Issue 1/2021
Print ISSN: 0114-9954
Electronic ISSN: 1179-2051
DOI: https://doi.org/10.1007/s40278-021-93391-1

Keynote webinar | Spotlight on medication adherence

Springer Medicine

TNF-alpha inhibitors: potential risk of mycosis fungoides

Excerpt

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 1/2021

Aspirin/clopidogrel

Carbamazepine

Doxylamine overdose

Antineoplastics

Azithromycin/tocilizumab

Lamotrigine